ABT-199/venetoclax (Fig. 2A) is a selective and the first FDA-approved BH3 mimetic binding to the BH3 binding groove of BCL-2 with high affinity and being described to be active in numerous cancer types (Vaillant et al. 2013; Bose et al. 2017; Hafezi and Rahmani 2021). Here, BCL2 is linked to cancer.